Publications

2018

Al-Tamari HM, Dabral S, Schmall A, Sarvari P, Ruppert C, Paik J, et al. FoxO3 an important player in fibrogenesis and therapeutic target for idiopathic pulmonary fibrosis. EMBO Mol Med. 2018;10(2):276-293.
Roszik J, Ring KL, Wani KM, Lazar AJ, Yemelyanova AV, Soliman PT, et al. Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy. Front Immunol. 2018;9:2102.
Zhai Y, Song W, Zeng J, Zhao Z, Cao Z. A 31-Year-Old Woman with Consecutive Pregnancy Losses. Clin Chem. 2018;64(5):777-780.
Soshnev AA, Josefowicz SZ, C Allis D. Greater Than the Sum of Parts: Complexity of the Dynamic Epigenome. Mol Cell. 2018;69(3):533.
Shiue K, Cerra-Franco A, Shapiro R, Estabrook N, Mannina EM, Deig CR, et al. Histology, Tumor Volume, and Radiation Dose Predict Outcomes in NSCLC Patients After Stereotactic Ablative Radiotherapy. J Thorac Oncol. 2018;13(10):1549-1559.
Mottahedeh J, Haffner MC, Grogan TR, Hashimoto T, Crowell PD, Beltran H, et al. CD38 is methylated in prostate cancer and regulates extracellular NAD. Cancer Metab. 2018;6:13.
Kumar B, Rosenberg AZ, Choi SM, Fox-Talbot K, De Marzo AM, Nonn L, et al. Cell-type specific expression of oncogenic and tumor suppressive microRNAs in the human prostate and prostate cancer. Sci Rep. 2018;8(1):7189.
Ooki A, Dinalankara W, Marchionni L, Tsay J-, Goparaju C, Maleki Z, et al. Epigenetically regulated PAX6 drives cancer cells toward a stem-like state via GLI-SOX2 signaling axis in lung adenocarcinoma. Oncogene. 2018;37(45):5967-5981.
Zadra G, Loda M. Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities. Cold Spring Harb Perspect Med. 2018;8(10).
Nayar R, Barkan GA, Benedict C, Booth C, Chhieng DC, Mody D, et al. Laboratory management curriculum for cytopathology subspecialty training. J Am Soc Cytopathol. 2018;7(2):61-78.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700